Sequenom同加州大学合作评估新型液体活检技术

  近日，Sequenom公司宣布，他们将同加州大学合作来调查其公司的液体活检分析技术在黑色素瘤患者中的应用。
  作为合作的一部分，合作者将评估Sequenom公司的技术来帮助确定是否循环肿瘤DNA的特性分析可以用于监测黑色素瘤患者对疗法的反应及复发率。
  Sequenom公司首席营销官Daniel Grosu指出，这项合作研究是公司首个关注黑色素瘤的研究，其或将扩张癌症及临床护理的范围，而且Sequenom公司也将会开发新型技术来不断满足研究的需要。
  目前，Sequenom公司正在开发仅用于实验测试的研究，重点关注晚期非血液恶性肿瘤的检测及分子特性分析，该测试获奖覆盖一系列癌症，并且可以帮助分析超过100种癌症相关的基因，而这些基因和美国FDA批准的药物疗法直接相关，包括专业的指导准则等；公司表示，这种新型实验技术和当前用于临床试验中的靶向疗法相关，而且部分和已经确凿的癌症通路直接相关。
  这项交易是Sequenom公司本月第三项液体活检技术的交易，上周，Sequenom公司还同汉堡-埃彭多夫大学医学院(University Medical Center Hamburg-Eppendorf)签署了一项合作协议来评估结直肠癌的新型检测技术；本月早些时候，该公司还宣布同首尔大学医院(Seoul National University Hospital)开展合作对血液中的无细胞的循环肿瘤DNA进行特性分析研究。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Sequenom, UC School of Medicine to Assess Liquid Biopsy Technology

Sequenom today announced a collaboration with the University of Colorado Denver, School of Medicine to investigate the use of the company's liquid biopsy assay in melanoma patients. 

As part of the collaboration, the partners will evaluate Sequenom's technology to determine whether circulating tumor DNA profiling has use for monitoring treatment response and relapse in melanoma patients. 

Sequenom CMO Daniel Grosu noted that the collaborative study is the firm's first focused on melanoma, and it expands the range of cancers and clinical care settings that Sequenom is exploring for its technology. 

Sequenom is currently developing its research-use-only assay with an initial focus on detecting and molecularly profiling late-stage non-hematologic malignancies. The assay will cover a number of cancers and analyze more than 100 cancer-related genes that are associated with a US Food and Drug Administration-approved drug treatment, included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways, the company said. 

The deal is the company's third this month for its liquid biopsy technology. Last week, Sequenom and University Medical Center Hamburg-Eppendorf signed an agreement to evaluate the technology for colorectal cancer. Earlier in the month, the firm announced a collaboration with Seoul National University Hospital to profile circulating cell-free tumor DNA in blood.